IOTA Pharmaceuticals Ltd, based in Cambridge, UK, and Vitas-M Laboratory Ltd, based in Moscow, Russia, have joined forces to design and market the next generation of fragment-based drug discovery libraries for early-stage drug discovery.

The IOTA Pharmaceuticals - Vitas-M Laboratory collaboration couples IOTA Pharmaceuticals analysis and screening platforms to Vitas-M Laboratory's established chemical synthesis capabilities, to produce a new 4,000-component fragment-based drug discovery (FBDD) screening set. This fragment set is being distributed by both companies immediately.

Access to a diverse set of FBDD library compounds enables the rapid progression of new discovery programs from concept to optimised lead, as described in detail on the IOTA website.

Vitas-M Laboratory is a specialist organic chemistry company which synthesises drug compounds for the pharmaceutical and biotechnology screening markets. For more information about Vitas-M Laboratory, please visit www.vitasmlab.com .